These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 12110154)
1. How does infliximab work in rheumatoid arthritis? Maini RN; Feldmann M Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154 [TBL] [Abstract][Full Text] [Related]
2. Emerging biologic drugs for the treatment of rheumatoid arthritis. Puppo F; Murdaca G; Ghio M; Indiveri F Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092 [TBL] [Abstract][Full Text] [Related]
3. Differentiating the efficacy of tumor necrosis factor inhibitors. Haraoui B J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457 [TBL] [Abstract][Full Text] [Related]
4. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483 [TBL] [Abstract][Full Text] [Related]
5. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184 [TBL] [Abstract][Full Text] [Related]
6. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Buch MH; Conaghan PG; Quinn MA; Bingham SJ; Veale D; Emery P Ann Rheum Dis; 2004 Oct; 63(10):1344-6. PubMed ID: 15033655 [TBL] [Abstract][Full Text] [Related]
7. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Bondeson J; Maini RN Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis]. Okada Y; Nawata M; Tanaka Y Clin Calcium; 2007 Nov; 17(11):1762-8. PubMed ID: 17982198 [TBL] [Abstract][Full Text] [Related]
10. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Takeuchi T; Yamanaka H; Inoue E; Nagasawa H; Nawata M; Ikari K; Saito K; Sekiguchi N; Sato E; Kameda H; Iwata S; Mochizuki T; Amano K; Tanaka Y Mod Rheumatol; 2008; 18(5):447-54. PubMed ID: 18493716 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis]. Imagama T; Taguchi T Nihon Rinsho; 2013 Jul; 71(7):1209-13. PubMed ID: 23961668 [TBL] [Abstract][Full Text] [Related]
12. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)]. Hirohata S Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049 [TBL] [Abstract][Full Text] [Related]
14. [How I treat...rheumatoid arthritis. The arrival of a new therapeutic era: anti-tumor necrosis factor alpha antibodies]. Kaiser MJ; Malaise MG Rev Med Liege; 2002 Aug; 57(8):486-92. PubMed ID: 12405019 [TBL] [Abstract][Full Text] [Related]
15. Infliximab treatment of rheumatoid arthritis. Maini SR Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044 [TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor inactivation in the management of rheumatoid arthritis. Baumgartner SW South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503 [TBL] [Abstract][Full Text] [Related]
17. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258 [TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. St Clair EW Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627 [TBL] [Abstract][Full Text] [Related]
19. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation. Novak S; Anić B; Anić F; Cerovac M; Cikeš N Acta Dermatovenerol Croat; 2011; 19(3):156-60. PubMed ID: 21933639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]